First-in-Human, Open-Label, Dose-Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of GEN1078 in Subjects With Malignant Solid Tumors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs GEN 1078 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genmab
- 20 Jan 2025 New trial record